Cargando…
Cholesterol-modifying drugs in COVID-19
Infection with severe acute respiratory syndrom coronavirus 2 (SARS-CoV-2) is more likely to lead to poor outcomes in the elderly and those with cardiovascular disease, obesity or metabolic syndrome. Here, we consider mechanisms by which dyslipidaemia and the use of cholesterol-modifying drugs could...
Autores principales: | Schmidt, Nathalie M, Wing, Peter A C, McKeating, Jane A, Maini, Mala K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337782/ https://www.ncbi.nlm.nih.gov/pubmed/33047740 http://dx.doi.org/10.1093/oxfimm/iqaa001 |
Ejemplares similares
-
A PCR assay to quantify patterns of HBV transcription
por: D’Arienzo, Valentina, et al.
Publicado: (2019) -
Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission()
por: Meredith, L.W., et al.
Publicado: (2013) -
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint
por: Schmidt, Nathalie M., et al.
Publicado: (2021) -
Trends in cholesterol testing during the COVID-19 pandemic: COVID-19 and cholesterol testing
por: Gumuser, Esra D., et al.
Publicado: (2021) -
Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies
por: Kasmas, S.H., et al.
Publicado: (2012)